Augmenting NK cell-based immunotherapy by targeting mitochondrial apoptosisNK cells are an attractive option for cell-based therapy but require optimization. BH3 mimetics chosen by BH3 profiling synergized with NK cell therapy to enhance cancer-cell killing by NK cells in an approach that could also be used for other cell therapy platforms.NK cells are an attractive option for cell-based therapy but require optimization. BH3 mimetics chosen by BH3 profiling synergized with NK cell therapy to enhance cancer-cell killing by NK cells in an approach that could also be used for other cell therapy platforms.Rongqing Pan, Jeremy Ryan, Deng Pan, Kai W. Wucherpfennig, Anthony Letaihttps://secure.jbs.elsevierhealth.com/action/getSharedSiteSession?redirect=https%3A%2F%2Fwww.cell.com%2Fcell%2Ffulltext%2FS0092-8674%2822%2900340-3%3Frss%3Dyes&rc=0http://www.cell.com/cell/inpress.rssCellCell RSS feed.Wireless News CampaignApril 21, 2022

Powered by WPeMatico